Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1996 2
1997 3
1998 4
1999 4
2000 1
2001 6
2002 2
2003 4
2004 8
2005 4
2006 1
2007 4
2008 2
2009 1
2011 2
2012 3
2014 1
2016 2
2017 2
2019 1
2021 3
2022 4
2023 6
2024 8
2025 10

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

81 results

Results by year

Filters applied: . Clear all
Page 1
Ocrelizumab versus Interferon Beta-1a in Relapsing Multiple Sclerosis.
Hauser SL, Bar-Or A, Comi G, Giovannoni G, Hartung HP, Hemmer B, Lublin F, Montalban X, Rammohan KW, Selmaj K, Traboulsee A, Wolinsky JS, Arnold DL, Klingelschmitt G, Masterman D, Fontoura P, Belachew S, Chin P, Mairon N, Garren H, Kappos L; OPERA I and OPERA II Clinical Investigators. Hauser SL, et al. Among authors: masterman d. N Engl J Med. 2017 Jan 19;376(3):221-234. doi: 10.1056/NEJMoa1601277. Epub 2016 Dec 21. N Engl J Med. 2017. PMID: 28002679 Free article. Clinical Trial.
Ocrelizumab versus Placebo in Primary Progressive Multiple Sclerosis.
Montalban X, Hauser SL, Kappos L, Arnold DL, Bar-Or A, Comi G, de Seze J, Giovannoni G, Hartung HP, Hemmer B, Lublin F, Rammohan KW, Selmaj K, Traboulsee A, Sauter A, Masterman D, Fontoura P, Belachew S, Garren H, Mairon N, Chin P, Wolinsky JS; ORATORIO Clinical Investigators. Montalban X, et al. Among authors: masterman d. N Engl J Med. 2017 Jan 19;376(3):209-220. doi: 10.1056/NEJMoa1606468. Epub 2016 Dec 21. N Engl J Med. 2017. PMID: 28002688 Free article. Clinical Trial.
Etiology of White Matter Hyperintensities in Autosomal Dominant and Sporadic Alzheimer Disease.
Shirzadi Z, Schultz SA, Yau WW, Joseph-Mathurin N, Fitzpatrick CD, Levin R, Kantarci K, Preboske GM, Jack CR Jr, Farlow MR, Hassenstab J, Jucker M, Morris JC, Xiong C, Karch CM, Levey AI, Gordon BA, Schofield PR, Salloway SP, Perrin RJ, McDade E, Levin J, Cruchaga C, Allegri RF, Fox NC, Goate A, Day GS, Koeppe R, Chui HC, Berman S, Mori H, Sanchez-Valle R, Lee JH, Rosa-Neto P, Ruthirakuhan M, Wu CY, Swardfager W, Benzinger TLS, Sohrabi HR, Martins RN, Bateman RJ, Johnson KA, Sperling RA, Greenberg SM, Schultz AP, Chhatwal JP; Dominantly Inherited Alzheimer Network and the Alzheimer’s Disease Neuroimaging Initiative. Shirzadi Z, et al. JAMA Neurol. 2023 Dec 1;80(12):1353-1363. doi: 10.1001/jamaneurol.2023.3618. JAMA Neurol. 2023. PMID: 37843849 Free PMC article.
Frequency and Clinical Outcomes Associated With Tau Positron Emission Tomography Positivity.
Moscoso A, Heeman F, Raghavan S, Costoya-Sánchez A, van Essen M, Mainta I, Camacho V, Rodríguez-Fonseca O, Silva-Rodríguez J, Perissinotti A, Gu Y, Yun J, Peretti D, Ribaldi F, Coomans EM, Brum WS, Grothe MJ, Aguiar P, Bischof GN, Drzezga A, Seo SW, Villeneuve S, Malpetti M, O'Brien JT, Rowe JB, van de Giessen EM, Ossenkoppele R, Jagust WJ, Smith R, Hansson O, Frisoni GB, Garibotto V, Soleimani-Meigooni DN, Carrillo M, Dickerson BC, La Joie R, Rabinovici GD, Apostolova LG, LaMontagne PJ, Pontecorvo MJ, Johnson KA, Sperling RA, Weiner MW, Petersen RC, Jack CR Jr, Vemuri P, Schöll M; PREVENT-AD Research Group, the Harvard Aging Brain Study, the LEADS Consortium, and the Alzheimer’s Disease Neuroimaging Initiative. Moscoso A, et al. JAMA. 2025 Jul 15;334(3):229-242. doi: 10.1001/jama.2025.7817. JAMA. 2025. PMID: 40522652
Enhancing cognitive performance prediction by white matter hyperintensity connectivity assessment.
Petersen M, Coenen M, DeCarli C, De Luca A, van der Lelij E; Alzheimer’s Disease Neuroimaging Initiative; Barkhof F, Benke T, Chen CPLH, Dal-Bianco P, Dewenter A, Duering M, Enzinger C, Ewers M, Exalto LG, Fletcher EM, Franzmeier N, Hilal S, Hofer E, Koek HL, Maier AB, Maillard PM, McCreary CR, Papma JM, Pijnenburg YAL, Schmidt R, Smith EE, Steketee RME, van den Berg E, van der Flier WM, Venkatraghavan V, Venketasubramanian N, Vernooij MW, Wolters FJ, Xu X, Horn A, Patil KR, Eickhoff SB, Thomalla G, Biesbroek JM, Biessels GJ, Cheng B. Petersen M, et al. Brain. 2024 Dec 3;147(12):4265-4279. doi: 10.1093/brain/awae315. Brain. 2024. PMID: 39400198 Free PMC article.
Towards cascading genetic risk in Alzheimer's disease.
Altmann A, Aksman LM, Oxtoby NP, Young AL; ADNI; Alexander DC, Barkhof F, Shoai M, Hardy J, Schott JM. Altmann A, et al. Brain. 2024 Aug 1;147(8):2680-2690. doi: 10.1093/brain/awae176. Brain. 2024. PMID: 38820112 Free PMC article.
Determinants of cognitive and brain resilience to tau pathology: a longitudinal analysis.
Bocancea DI, Svenningsson AL, van Loenhoud AC, Groot C, Barkhof F, Strandberg O, Smith R; Alzheimer’s Disease Neuroimaging Initiative; La Joie R, Rosen HJ, Pontecorvo MJ, Rabinovici GD, van der Flier WM, Hansson O, Ossenkoppele R. Bocancea DI, et al. Brain. 2023 Sep 1;146(9):3719-3734. doi: 10.1093/brain/awad100. Brain. 2023. PMID: 36967222 Free PMC article.
Evaluation of the Revised Criteria for Biological and Clinical Staging of Alzheimer Disease.
Pichet Binette A, Smith R, Salvadó G, Tideman P, Glans I, van Westen D, Groot C, Ossenkoppele R, Stomrud E, Parchi P, Zetterberg H, Blennow K, Mattsson-Carlgren N, Janelidze S, Palmqvist S, Hansson O; Alzheimer’s Disease Neuroimaging Initiative. Pichet Binette A, et al. JAMA Neurol. 2025 Jul 1;82(7):666-675. doi: 10.1001/jamaneurol.2025.1100. JAMA Neurol. 2025. PMID: 40388185 Free PMC article.
Plasma Phosphorylated Tau 217 to Identify Preclinical Alzheimer Disease.
Salvadó G, Janelidze S, Bali D, Dolado AO, Therriault J, Brum WS, Pichet Binette A, Stomrud E, Mattsson-Carlgren N, Palmqvist S, Coomans EM, Teunissen CE, van der Flier WM, Rahmouni N, Benzinger TLS, Gispert JD, Blennow K, Doré V, Feizpour A, Rowe CC, Alcolea D, Fortea J, Villeneuve S, Johnson SC, Rosa-Neto P, Petersen RC, Jack CR Jr, Schindler SE, Suárez-Calvet M, Ossenkoppele R, Hansson O; ADNI, ALFA, and PREVENT-AD Study Groups. Salvadó G, et al. JAMA Neurol. 2025 Nov 1;82(11):1122-1134. doi: 10.1001/jamaneurol.2025.3217. JAMA Neurol. 2025. PMID: 40952756 Free PMC article.
81 results